Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Crucell   /   Sanofi, Sanofi en nog eens Sanofi

Crucell« Terug naar discussie overzicht

Sanofi, Sanofi en nog eens Sanofi

Volgen
785 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 40 »» | Laatste | Omlaag ↓
  1. [verwijderd] 14 februari 2009 09:39
    Sanofi will weg vom Blockbuster-Prinzip
    13.02.09 Kleinvieh macht auch Mist. Das denkt sich Chris Viehbacher, seit Dezemebr 2008 neuer CEO des französischen Pharmakonzerns Sanofi-Aventis. Bei der Vorstellung der Jahresergebnisse verkündete Viehbacher einen radikalen Strategiewechsel des Konzerns. In Zukunft werde man auf viele kleine Erfolgsträger setzen. Ein Sortiment mit wenigen Kassenschlagern sei nicht mehr zeitgemäß, so Viehbacher. "Wir wollen weg vom reinen Blockbuster-Modell." Da die geplante Diversifizierung aber nicht aus der eigenen Pipeline zu bewerkstelligen ist, will man bei Sanofi demnächst zukaufen - im kleinen bis mittleren Bereich. Firmen bis maximal 15 Milliarden Euro Marktwert kommen demnach in Betracht, vor allem im Bereich Impfstoffe, Generika und rezeptfreie Wirkstoffe. Bis zu fünf Übernahmen pro Jahr kann sich Viehbacher vorstellen. Dafür soll eigens der Posten eines Chief Strategy Officers geschaffen werden. Als interessante Übernahme-Kandidaten nannte Viehbacher den Ulmer Generika-Hersteller ratiopharm, aber auch das niederländische Biotech-Unternehmen Crucell, dessen Übernahme durch Wyeth mit dessen Fusion von Pfizer vom Tisch ist. Die Börse nahm den Strategieschwenk bei Sanofi vor diesem Hintergrund positiv auf und erfreute sich an den soliden Gewinnzahlen: Der Nettogewinn des Konzerns erreichte 7,1 Mrd. Euro und stieg damit - bereinigt um Währungseffekte und Zu- oder Verkäufe - um 3,2 Prozent. Damit erweist sich Sanofi bislang als erstaunlich krisenfest.
    Zurück zu: |transkript
    Jeden Monat neu
    Lesen Sie |transkript - das führende Nachrichten- Magazin für Life Sciences in Europa (D/A/CH):

    Kostenloses Probeheft

    Heft durchblättern

    Zum |transkript-Abo!


    © 2007-2009 BIOCOM Verlag | Impressum iGoogle | RSS-Feed | Artikel empfehlen | Drucken
  6. flosz 14 februari 2009 10:08
    De vier hoofdtalen van Zwitserland zijn Duits (65%), Frans (18%), Italiaans (10%) en Raeto-Romaans (1%). Het merendeel van de bevolking is tweetalig. In de Zwitserse grondwet van 1938 is vastgelegd dat alle talen officiëel en rechtsgelijk zijn. Het merendeel van de Duitssprekende Zwitsers spreekt bovendien nog Schwyzerdütsch, een variant van het Duits en zeer moeilijk te verstaan.
    De meeste kantons hebben één officiële taal. Alleen in het kanton Graubünden spreekt men Duits, Italiaans en Raeto-Romaans. In de kantons Vaud, Neuchâtel en Genève is Frans de overheersende taal. In Ticino is dat het Italiaans. In Bern, Fribourg en Wallis Duits en Frans. In de overige kantons is Duits/Schwyzerdütsch de voertaal. De viertaligheid ontstond toen de Bourgondiërs en de Alemannen na volksverhuizing rond de 6e eeuw de Franse taal in het westen en de Duitse taal in het oosten verspreidden. Tot dan toe sprek men in “Helvetië” Latijn. Dat Latijn gaat terug tot de Romeinse overheersing. De Alemannen en daarmee de Duitse taal slaagden er niet in om die gebieden te bereiken. Zo ontwikkelde zich een soort volkslatijn dat uitgroeide tot een zelfstandige taal die in 1938 als vierde officiële taal erkend werd. Het aantal dialecten is in alle talen, vooral in het Duits sprekende gedeelte, zeer groot.
    zwitserland.credylco.com/product_1.htm
  7. flosz 15 februari 2009 11:36
    Viehbacher applies Glaxo lessons at Sanofi
    Sun Feb 15, 2009
    By Ben Hirschler, European Pharmaceuticals Correspondent
    LONDON, Feb 15 (Reuters) - Chris Viehbacher, the new chief executive of French drugmaker Sanofi-Aventis SA (SASY.PA), could hardly have hoped for a better start.
    Sanofi stock leapt 8 percent, or $6 billion, after he set out his strategy for the first time on Feb. 11 alongside 2008 results that met market expectations.
    But the former GlaxoSmithKline Plc (GSK.L) executive, in the Sanofi job just 11 weeks, knows he has his work cut out to rebuild investor confidence in the world's third-largest seller of pharmaceuticals, following a string of high-profile setbacks.
    His answer is diversification via small and mid-sized acquisitions in vaccines, generics and over-the-counter drugs, and an overhaul of research to shift the focus away from chasing "blockbusters" and put greater emphasis on outside alliances.
    The aim is to make Sanofi a low-risk healthcare business with a global footprint.
    It is a very similar strategy to that adopted by Glaxo's new boss Andrew Witty, who beat Viehbacher to the top job at the British-based group in 2007.
    James Knight, an industry analyst at stockbroker Collins Stewart, says it is none the worse for that.
    "He's got a good chance because he comes from a business in GlaxoSmithKline that has some of the answers to some of the challenges that Sanofi is facing," Knight said.
    "The ideas on R&D strategy, cost cutting and making the portfolio more rounded from a products and geographic point of view are important steps in repositioning Sanofi in investors' minds."
    Certainly, Viehbacher could do worse than emulate the stock market rating of Glaxo, which has many of the same problems of generic competition and unproven new drugs but whose shares trade on 10.5 times forecast 2009 earnings versus Sanofi's 7.9.
    In the past, Sanofi has stressed scientific innovation and boasted of its large portfolio of experimental drugs as evidence it can overcome the potential loss of more than a fifth of its current drug sales to generic rivals by 2012.
    But investor confidence in the commercial potential of the pipeline has been weak -- especially after the failure of weight loss drug Acomplia, which was finally pulled from development last year after being linked to psychiatric problems.
    Viehbacher is taking a tougher line on research by terminating poor quality projects. That will cut R&D spending over the next year and should trigger widespread earnings upgrades, according to Morgan Stanley analyst Andrew Baum.
    CULTURE CHANGE
    In addition to changing operations, Viehbacher also brings a change of culture, as a non-French outsider parachuted into a pillar of France's corporate establishment.
    In contrast to predecessor Gerard Le Fur, who was ousted last September after less than two years in the job, Viehbacher, has widespread international experience from his 20 years at Glaxo, most recently as head of its U.S. business.
    The 48-year-old is a dual citizen of Canada and Germany, who also speaks French.
    A key priority for him is improving communications with investors -- an area where Sanofi has been perceived as weak.
    For now, shareholders are clearly on his side. But execution on strategy will be critical and Viehbacher still has to navigate the ups and downs of news flow in 2009.
    On the positive side, Sanofi has a chance next month to prove its research laboratories can still deliver when heart drug Multaq goes before a U.S. Food and Drug Administration committee, a step that could pave the way for 2009 approval.
    But there is also the danger of a generic competitor to top-selling anticoagulant drug Lovenox emerging this year.
    Other risks include any move by Total SA (TOTF.PA) to sell down its 13 percent stake and the possibility that Sanofi follows Pfizer Inc (PFE.N) in acquiring a large-cap drugmaker, according to Citigroup analyst Mark Dainty.
    Viehbacher said last week he was not considering such a mega-deal, but he did not rule out any strategic option. (Editing by Dan Lalor)
    uk.reuters.com/article/mnaNewsEnergy/...
  8. flosz 16 februari 2009 08:28
    Francezii au un buget de achizitii de pana la 15 miliarde de euro, alti producatori precum Crucell din Olanda si Bristol-Myers Squibb din Statele Unite ale Americii fiind vizati pentru o posibila noua tranzactie. Tendinta de consolidare pe orizontala si chiar pe verticala din industria farmaceutica va continua si la nivel european si pot aparea miscari surprinzatoare.
    www.businessmagazin.ro/analize/indust...
  10. TraderRon 16 februari 2009 14:04
    Brazil’s Medley in Sale Talks With Sanofi-Aventis, Valor Says
    Email | Print | A A A

    By Francisco Marcelino

    Feb. 16 (Bloomberg) -- Brazilian generic-drug maker Medley SA is in sale talks with Sanofi-Aventis SA, Valor Economico reported, citing unidentified people familiar with the negotiations.

    The Paris-based company may pay more than 500 million reais ($221 million) to Medley’s controlling shareholders, the Negrao family, the Sao Paulo-based newspaper said.

    Sanofi-Aventis spokesman Jean-Marc Podvin didn’t immediately return a call from Bloomberg seeking comment.
    BRON: www.bloomberg.com/apps/news?pid=20601...
  12. flosz 16 februari 2009 14:25
    Medley is also present in Brazilian car racing, in the Stock Car category, with the drivers Guto Negrão and Giuliano Lossaco.
    www.medley.com.br/src/area.asp?areaid...

    Medley operates in the areas of Farma drugs, generics and OTC. Currently, it ranks sixth in the pharmaceutical companies classification, or third, considering only wholly-owned Brazilian companies. Medley´s products: 88 million units produced in 2003 and 94 million produced in 2004. Over the last four years, 350 million units have been produced.
    Medley is the leader in generics launches in Brazil. In order to maintain and consolidate this position, the company has been dedicating itself to identifying strategies that can bring a sustainable competitive advantage and to increasing its knowledge to invest in the expansion of new therapeutic classes.
    In line with its values of transparency and commitment, Medley constantly invests in the information to consumers on this product category and reinforces its presence at the point of sale with television campaigns, merchandising and sports sponsorships. The health professionals also have a key role in the evolution of the company. Often times, it is from them that an indication for the improvement and innovation of Medley’s products arises, facilitating product use and increasing the effectiveness of the prescribed treatment. Proximity in relationships enables Medley to capture these needs and to propose creative solutions through its drugs.
    Among the twenty top sold generics in the market, ten are from Medley (IMS Health).
    Medley’s development continues to expand into markets where it already has a strong presence, such as in 15 Latin American countries, as well as with the opening of new fronts in Europe. This expansion has come about through the export of finished and semi-finished products as well as through cooperation agreements and licenses.

    In the case of Mexico, for instance, the company increased its exports of combination products, which concentrate, under the same package, various substances for a determined treatment – an innovative concept which is sold in Brazil as a “pack”.

    Helaas, zit een slotje op.
    www.valoronline.com.br/Busca.aspx
  14. flosz 17 februari 2009 13:42

    www.youtube.com/watch?v=i1tsa2DaL2g
    **************************

    Sanofi-Aventis (SASY.PA) has no comment on newspaper reports it is in takeover talks with Brazilian generic drugmaker Medley, the world's third largest drugmaker said.
    French newspapers Les Echos and La Tribune, citing a report in Brazilian newspaper Valor Economico, said that Sanofi was interested in buying Brazil's biggest generics drugmaker, which is valued at $220 million. [ID:nLH310572] (Compiled by Tina Kwan in Singapore; R. Manikandan in Bangalore)
    www.reuters.com/article/americasRegul...
  15. [verwijderd] 25 februari 2009 10:08
    Sanofi-Aventis slaagt in overname Zentiva

    AMSTERDAM (Dow Jones)--Sanofi-Aventis SA is erin geslaagd de Tsjechische generieke medicijnenmaker Zentiva nv over te nemen. Na een overnamestrijd van zeven maand houdt het Franse farmaceutische concern 94% van het aandelenkapitaal van Zentiva na de overdracht van de aangemelde aandelen op 11 maart.

    Door de overname wordt Sanofi-Aventis de op tien na grootste maker van generieke medicijnen ter wereld, met activiteiten in Oost-Europa, Turkije en Rusland.

    Sanofi-Aventis, dat al een belang van 24,9% in Zentiva had, bracht in juni 2008 een bod uit op Zentiva dat hoger lag dan het eerdere bod van het Tsjechische investeringsbedrijf PPF Group nv. Sanofi-Aventis bood CZK1.150 per aandeel Zentiva, waarmee het bedrijf werd gewaardeerd op EUR1,8 miljard.

    Het Franse concern had een controlerend belang nodig van meer dan 50% om het bod, dat op 20 februari afliep, te doen slagen. De Europese Commissie keurde de overname begin februari al goed.

    Het aandeel Sanofi-Aventis noteert woensdagochtend in Parijs zo'n 1,5% hoger op EUR44,87.


    - Door Martijn Mom; Dow Jones Nieuwsdienst; +31-20-5715 201; martijn.mom@dowjones.com



    (END) Dow Jones Newswires

    February 25, 2009 03:57 ET (08:57 GMT)

    Copyright (c) 2009 Dow Jones & Company, Inc.

785 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 40 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 3,039 +0,30 +10,89%
Flow Traders 21,560 +1,10 +5,38%
Accsys 0,598 +0,02 +3,10%
Alfen N.V. 12,435 +0,28 +2,26%
Fugro 17,030 +0,35 +2,10%
Brunel 8,750 +0,15 +1,74%
OCI 11,210 +0,16 +1,45%
THEON INTERNAT 9,230 +0,13 +1,43%
PROSUS 39,525 +0,52 +1,32%
AZERION 1,296 +0,02 +1,25%
AMG Critical Materials N.V. 15,600 +0,19 +1,23%
Wereldhave 14,160 +0,16 +1,14%
Fagron 18,840 +0,16 +0,86%
IMCD 146,500 +1,10 +0,76%
Van Lanschot Kempen NV 41,600 +0,30 +0,73%
Aperam 25,300 +0,18 +0,72%
SBM Offshore 16,980 +0,11 +0,65%
Avantium 2,355 +0,02 +0,64%
INPOST 17,810 +0,11 +0,62%
BAM 4,338 +0,03 +0,60%
TomTom 5,115 +0,03 +0,59%
Sif Holding 13,880 +0,08 +0,58%
Kendrion 11,000 +0,06 +0,55%
CTP 15,200 +0,08 +0,53%
UMG 23,100 +0,12 +0,52%
RELX 43,380 +0,22 +0,51%
SHELL PLC 31,350 +0,15 +0,46%
Eurocommercial Properties 23,200 +0,10 +0,43%
RENEWI 7,330 +0,03 +0,41%
ArcelorMittal 22,830 +0,09 +0,40%
TKH 36,560 +0,14 +0,38%
JDE PEET'S 19,380 +0,07 +0,36%
ADYEN NV 1.400,800 +5,00 +0,36%
ASCX 1.209,11 +3,83 +0,32%
NSI 19,640 +0,06 +0,31%
Vopak 41,460 +0,12 +0,29%
Wolters Kluwer 157,850 +0,45 +0,29%
UNILEVER PLC 56,500 +0,16 +0,28%
Aegon 5,846 +0,02 +0,27%
FASTNED 21,300 +0,05 +0,24%
AMX 865,51 +1,83 +0,21%
HEIJMANS KON 24,900 +0,05 +0,20%
AEX 880,52 +1,01 +0,11%
EXOR NV 96,750 +0,10 +0,10%
WDP 21,520 +0,02 +0,09%
Philips Koninklijke 25,030 +0,01 +0,04%
ASR Nederland 45,160 +0,01 +0,02%
Arcadis 64,900 0,00 0,00%
Basic-Fit 22,340 0,00 0,00%
Nedap N.V. 55,000 0,00 0,00%
Vastned 24,500 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
RANDSTAD NV 41,750 -0,95 -2,22%
JUST EAT TAKEAWAY 10,355 -0,23 -2,13%
PostNL 1,038 -0,01 -1,42%
NX FILTRATION 4,585 -0,06 -1,29%
Air France-KLM 8,810 -0,08 -0,94%
ING 15,714 -0,14 -0,86%
ABN AMRO BANK N.V. 15,295 -0,11 -0,68%
ALLFUNDS GROUP 5,490 -0,04 -0,63%
KPN 3,626 -0,02 -0,58%
DSM FIRMENICH AG 107,800 -0,60 -0,55%
BESI 100,050 -0,55 -0,55%
ForFarmers 3,375 -0,02 -0,44%
B&S Group SA 4,530 -0,02 -0,44%
Galapagos 24,620 -0,10 -0,40%
Pharming 0,761 0,00 -0,39%
Ahold Delhaize 30,700 -0,11 -0,36%
ASMI 505,800 -1,80 -0,35%
SIGNIFY NV 22,600 -0,08 -0,35%
ASML 616,400 -1,80 -0,29%
Corbion 23,080 -0,06 -0,26%
Akzo Nobel 58,520 -0,14 -0,24%
ACOMO 17,320 -0,04 -0,23%
Sligro 11,320 -0,02 -0,18%
CM.COM 6,410 -0,01 -0,16%
Heineken 74,360 -0,10 -0,13%
NN Group 45,840 -0,06 -0,13%
AALBERTS NV 33,300 -0,02 -0,06%
vlag naam koers verschil relatief verschil
AEX 880,45 +0,94 +0,11%
AEX GR 3.442,75 +3,51 +0,10%
Germany40^ 19.156,10 +8,25 +0,04%
FTSE 100 8.204,02 +19,78 +0,24%
EURO50 4.853,14 +8,01 +0,17%
US30^ 41.859,80 +62,40 +0,15%
Nasd100^ 20.023,20 +52,90 +0,26%
US500^ 5.723,34 +8,67 +0,15%
Japan225^ 38.601,10 +222,20 +0,58%
VD-NEW 19,55 +0,32 +1,67%
#/^ Index indications calculated real time, zie disclaimer